Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Levi, Francis
Parganiha, Arti
Karaboue, Abdoulaye
Innominato, Pasquale F.
Giacchetti, Sylvie
Garufi, Carlo
Dispersyn, Garance
Focan, C. N. J.
Iacobelli, Stefano
Bjarnason, Georg A.
Moreau, Thierry
Dugue, Pierre Antoine
Waterhouse, Jim
机构：
[1] Serv Chronotherapie, INSERM, Dep Cancerol, Hop Paul Brousse,U776, Villejuif, France
[2] Pt Ravishankar Shukla Univ, Sch Life Sci, Raipur, Madhya Pradesh, India
[3] Hop Paul Brousse, INSERM, U776, Villejuif, France
[4] INSERM, U776, Paris, France
[5] Regina Elena Inst Canc Res, Rome, Italy
[6] INSERM, Hop Paul Brousse, U776, Villejuif, France
[7] CHC Clin St Joseph, Liege, Belgium
[8] Univ G dAnnunzio, Chieti, Italy
[9] Mediapharma srl, Chieti, Italy
[10] Univ Toronto, Div Med Oncol Hematol, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[11] Hop Paul Brousse, INSERM, Res Epidemiol & Biostat, U780, Villejuif, France
[12] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool, Merseyside, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
464
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients
    Sjoquist, Katrin Marie
    Bokemeyer, Carsten
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Adams, Richard
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Heinemann, Volker
    Sougklakos, Ioannis
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
    Sjoquist, Katrin Marie
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Adams, Richard
    Seymour, Matthew T.
    Saltz, Leonard
    Schmoll, Hans
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [5] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [6] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [7] Identifying SNPs associated with progression-free survival (PFS) and overall survival (OS) in patients with KRAS wildtype and mutant metastatic colorectal cancer (mCRC) using Random Survival Forests (RSF).
    Yang, Dongyun
    Zhang, Wu
    Cao, Shu
    Loupakis, Fotios
    Schirripa, Marta
    Stintzing, Sebastian
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS
    Oh, Youjin
    Djunadi, Trie Arni
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Shah, Zunairah
    Park, Joo Hee
    Yoon, Sung Mi
    Duan, Richard
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1468 - A1469
  • [9] Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
    Venook, Alan P.
    Niedzwiecki, Donna
    Innocenti, Federico
    Fruth, Briant
    Greene, Claire
    O'Neil, Bert H.
    Shaw, James Edward
    Atkins, James Norman
    Horvath, Laura E.
    Polite, Blase N.
    Meyerhardt, Jeffrey A.
    O'Reilly, Eileen Mary
    Goldberg, Richard M.
    Hochster, Howard S.
    Blanke, Charles David
    Schilsky, Richard L.
    Mayer, Robert J.
    Bertagnolli, Monica M.
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
12345